Key facts
- It has raised $1.3M; the latest was Seed Round ($1.0M) in Mar 2025.
- Notable investors include Rabo Investments, Coöperatieve Rabobank., RUG Ventures, Chaperone Pharma, Coöperatieve Rabobank — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Cortalix
- ·The full record, as it builds
Funding rounds
No funding rounds for Cortalix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cortalix
Developer of a biotechnological platform designed for single-domain antibody (sdAb) discovery and development. The company's platform offers molecular imaging, targeted therapy, and immunotherapy for research bioanalytical applications, enabling clinicians to efficiently identify patients, target therapy, and monitor disease.
- Sector
- Healthcare
- HQ
- Groningen, Netherlands
- Founded
- 2023
- Employees
- 5
- Website
- cortalix.com/
- Ownership
- Privately Held (backing)
Cortalix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cortalix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cortalix in its N-PORT filings yet. We sweep new filings monthly.